RecruitingNot ApplicableNCT07281430

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial LMI-001-A-S04


Sponsor

National Cancer Institute (NCI)

Enrollment

500 participants

Start Date

Nov 24, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. HPV is known to cause a variety of cancers including cervical cancer. Even though there are ways to detect cervical cancer, many individuals are not diagnosed. Over half of all new cervical cancer cases are among those who have either never been screened or who are not screened enough. The low screening numbers show more testing needs to be done. Without appropriate screening and care, preventable precancer may turn into cancer. A new way to detect cervical cancer is to have individuals collect their own sample for HPV testing to know their risk for cervical cancer. This may give individuals more flexibility and comfort having the ability to collect samples themselves, compared to a doctor performing a speculum examination and collecting the samples in a clinic. Information gathered from this study compares clinical accuracy of HPV testing on self-collected vaginal samples versus cervical samples collected by clinician. The Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial is part of the National Cancer Institute (NCI)'s Cervical Cancer 'Last Mile' Initiative, a public private partnership that seeks to increase access to cervical cancer screening. The SHIP Trial focuses on developing clinical evidence to inform the US Food and Drug Administration (FDA)'s regulatory reviews of self-collection approaches as alternative sample collection approaches for cervical cancer screening. Several industry partner-specific self-collection device and assay combinations will be non-competitively and independently evaluated with a similar study design framework to inform pre-approval and/or post-approval regulatory requirements.


Eligibility

Sex: FEMALEMin Age: 25 Years

Inclusion Criteria5

  • Willingness and ability to provide a documented informed consent
  • Is 25 years or older
  • Has an intact cervix
  • Has had a referral for colposcopy in which routine cervical cancer screening has included positive HPV testing (HPV primary screening, co-testing, or atypical squamous cells of undetermined significance \[ASC-US\] cytology triage) or abnormal cytology performed within the past 12 months preceding the referral visit, and/or for cervical excisional procedure
  • Willing and able to undergo colposcopy, and if clinically indicated for SOC purposes, a biopsy, endocervical curettage, and/or a cervical excisional procedure, as applicable

Exclusion Criteria6

  • Is pregnant when presenting for the referral visit or gave birth within the past 3 months
  • Has a known history of excisional or ablative therapy to the cervix (e.g., loop electrosurgical excision procedure \[LEEP\], cone biopsy, cervical laser surgery, cryotherapy, thermal ablation) in the last 12 months prior to the referral visit
  • Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records
  • Known medical conditions that, in the opinion of the investigator, preclude study participation
  • Previous participation in the SHIP Trial or another cervical cancer screening study within the past 12 months. Participation is defined as completing the self-collection
  • Is experiencing unusual bleeding or pelvic pain

Interventions

PROCEDUREBiospecimen Collection

Undergo collection of a cervical sample by clinician

PROCEDURECervical Biopsy

Undergo cervical biopsy

PROCEDUREColposcopy

Undergo colposcopy

OTHERElectronic Health Record Review

Ancillary studies

PROCEDUREEndocervical Curettage

Undergo endocervical curettage

PROCEDUREExcision

Undergo cervical excisional procedure

PROCEDUREHPV Self-Collection

Undertake self-collection of vaginal sample

PROCEDUREHuman Papillomavirus Test

Undergo HPV testing of self-collected vaginal samples and cervical samples

OTHERQuestionnaire Administration

Ancillary studies


Locations(18)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, United States

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, United States

Louisiana State University

Lafayette, Louisiana, United States

Louisiana State University Health Science Center

New Orleans, Louisiana, United States

Minneapolis VA Medical Center

Minneapolis, Minnesota, United States

University of New Mexico Cancer Center

Albuquerque, New Mexico, United States

Montefiore Medical Center-Einstein Campus

The Bronx, New York, United States

Montefiore Medical Center-Weiler Hospital

The Bronx, New York, United States

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, United States

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

University of Oklahoma

Oklahoma City, Oklahoma, United States

University of Pennsylvania/Abramson Cancer Center

Philadelphia, Pennsylvania, United States

UPMC-Magee Womens Hospital

Pittsburgh, Pennsylvania, United States

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, United States

M D Anderson Cancer Center

Houston, Texas, United States

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, United States

West Virginia University Healthcare

Morgantown, West Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07281430


Related Trials